Synapse

← Tuyen Bui

Papers by Tuyen Bui

Page 1 · newest first

  1. Hybrid molecule SA-10 and its PLGA nanosuspension protect human and rodent retinal ganglion cells against neuronal injuryBMC Neuroscience · 2025
  2. IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancernpj Precision Oncology · 2025
  3. Data from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers2024
  4. Supplementary Materials and Methods from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers2024
  5. Supplemental Figures and Figure Legends from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers2024
  6. Supplementary Materials and Methods from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers2024
  7. Supplemental Figures and Figure Legends from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers2024
  8. Low Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast CancerCancer Research · 2024
  9. Abstract PO1-18-05: Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancerCancer Research · 2024
  10. Abstract PO3-15-03: Abemaciclib is effective in palbociclib resistant estrogen receptor positive breast cancersCancer Research · 2024
  11. Abstract PO1-25-08: Evaluating the role of CDK4/6 inhibition on STAT3 activation in a transgenic mouse model of HER2-positive breast cancerCancer Research · 2024
  12. Abstract PO1-16-04: Targeting PKMYT1 Kinase as a Therapeutic Strategy for Treatment of Triple Negative Breast Cancer with Low Molecular Weight Cyclin E (LMW-E) ExpressionCancer Research · 2024
  13. Abstract PO2-04-14: Dual Inhibition of WEE1 and PKMYT1 Synergistically Overcomes CDK4/6 Inhibitor Resistance in Breast CancerCancer Research · 2024
  14. Abstract 4622: Anti-tumor activity of CDK2 inhibitor BLU-222 in combination with CDK4/6 inhibitors for overcoming resistance in HR positive and triple negative metastatic breast cancers modelsCancer Research · 2024
  15. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast CancersCancer Research · 2023
  16. Data from Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer2023
  17. Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real TimeCancer Research · 2023
  18. LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancersOncogenesis · 2021
  19. Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 AlterationCancers · 2021
  20. Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancerBritish Journal of Cancer · 2020
  21. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast CancerClinical Cancer Research · 2019
  22. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase InhibitionClinical Cancer Research · 2018
  23. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast CancerCancer Research · 2017
  24. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancersNature Communications · 2017
  25. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle ArrestMolecular Cancer Therapeutics · 2017
  26. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple CancersMolecular Cancer Research · 2016
  27. Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer CellsCancer Research · 2016
  28. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast CancerMolecular Cancer Therapeutics · 2016
  29. Staurosporine is chemoprotective by inducing G 1 arrest in a Chk1- and pRb-dependent mannerCarcinogenesis · 2013
  30. EVI1 splice variants modulate functional responses in ovarian cancer cellsMolecular Oncology · 2013
  31. Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin ECancer Research · 2011
  32. Cyclin E Deregulation Impairs Mitotic Progression through Premature Activation of Cdc25CCancer Research · 2010
  33. Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and TumorsClinical Cancer Research · 2010
  34. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progressionCell Cycle · 2009
  35. Differential Regulation of Elafin in Normal and Tumor-Derived Mammary Epithelial Cells Is Mediated by CCAAT/Enhancer Binding Protein βCancer Research · 2007
  36. Undermethylated DNA as a source of microsatellites from a conifer genomeGenome · 2002